The rituximab biosimilar Rixathon® (GP2013) was approved by the European Medicines Agency and launched in the UK in June 2017. It is licensed for the same indications as the reference medicine (MabThera®).
The first biosimilar version of rituximab (Truxima®) was approved in Europe in February 2017 and launched in the UK in April 2017. A briefing sheet intended to support prescribers by providing answers to commonly asked questions about the introduction of this medicine (published April 2017) is available at the link below.